

DaVita to Present 13 Abstracts at the National Kidney Foundation's 2012 Spring Clinical Meeting

WASHINGTON--(BUSINESS WIRE)--May. 10, 2012-- [DaVita Inc.](#) (NYSE: DVA), a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease, today announced that company representatives will present 13 abstracts at this year's National Kidney Foundation (NKF) Spring Clinical Meeting held in Washington, D.C., May 9-13.

NKF's Spring Clinical Meeting is a valuable opportunity for renal health care providers to learn new developments related to all aspects of nephrology. This annual meeting highlights the needs and interests of kidney care practitioners including doctors in the private sector and academia, nurses, dialysis technicians, social workers, and dietitians, as well as, fellows and residents with a special interest in kidney disease.

"DaVita continuously strives to enhance kidney care for our patients and improve clinical outcomes for the industry," said Dr. Mahesh Krishnan, vice president of DaVita Clinical Research. "These studies reflect DaVita's ongoing commitment to the kidney care community and patients with end-stage renal disease."

Presented this year are the results from a number of innovative clinical improvement programs and health economic studies originating from DaVita® and its research partners. Abstract highlights include the following.

- *Video Education Increases Patient Knowledge About Phosphorus Control and Is a Preferred Form of Education* (Duane Dunn, et al.; abstract #134)
- *Improvement in Peritonitis Rates with the Use of Sodium Hypochlorite* (Dr. John Moran, et al.; abstract #248)
- *Disease Management Program Reduces Overall Medical Costs in End-Stage Renal Disease Patients* (Dr.Allen R. Nissenson, et al.; abstract #149)
- *Results of a One-Year Assessment of Quality Indicators in an Acute Dialysis Program Operated by a Large Dialysis Provide* (Dr. Robert Provenzano, et al.; abstract #21)
- *Crit-Line Monitor Use in Incident Hemodialysis Patients Improves Dry Weight and Adequacy, While Reducing Epoetin Alfa Dose: a Propensity Score Matched Study* (Scott Sibbel, PhD et al.; abstract #184)

Researchers from DaVita Clinical Research® (DCR®) and DaVita will present their findings at the NKF meeting. DCR provides a collaborative bridge between DaVita services and the pharmaceutical and biotech research community. DCR shares DaVita's dedication to improving the health and well-being of kidney patients.

DaVita, DaVita Clinical Research and DCR are registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita

DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of March 31, 2012, DaVita operated or provided administrative services at 1,841 outpatient dialysis centers located in the United States serving approximately 145,000 patients. The company also operated 15 outpatient dialysis centers located in three countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company's leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit www.davita.com.

About DaVita Clinical Research (DCR)

[DaVita Clinical Research](#) (DCR), a wholly owned subsidiary of DaVita Inc., is committed to advancing the knowledge and practice of kidney care. DCR brings knowledge, skill and expertise to pharmaceutical research, facilitating the success of its clients' clinical trials. DCR's clinical expertise spans the lifecycle of drug development. DCR's [biorepository](#), [Early Clinical Research](#) unit (Phase I-IIa) and [Clinical Development](#) network of physicians and investigative sites, data research, [Health Economics & Outcomes Research](#), [Central Laboratory](#), [Advisory Committee prep](#), and [Medical Communications](#) are focused on providing world-class clinical research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.

DaVita Inc.
Bianca Violante, 303-405-2363
Bianca.Violante@davita.com

<https://newsroom.davita.com/press-releases?item=122886>